Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04359550
Recruitment Status : Not yet recruiting
First Posted : April 24, 2020
Last Update Posted : April 29, 2020
Information provided by (Responsible Party):
Lee's Pharmaceutical Limited

Brief Summary:
It is a randomized, double-blind, placebo-controlled, multicenter study with the sample size is 362. The patients with high-grade osteosarcoma who had previously received surgery and completed adjuvant chemotherapy will be randomly assigned to ZKAB001 group (trial group) or placebo group (control group) according to 1:1. The purpose is to evaluate the efficacy and safety of ZKAB001 in maintenance therapy after adjuvant chemotherapy in patients with high-grade osteosarcoma.

Condition or disease Intervention/treatment Phase
High-grade Osteosarcoma Biological: Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001) Other: placebo Phase 3

Detailed Description:

The patients will be given ZKAB001 injection in 10mg/kg or placebo once every 3 weeks for a total of 16 cycles or 1 year. The end point is that the patient has been taking the drug for 16 cycles or 1 year, or the patient dies or develops intolerable toxicity or confirmed disease recurrence or distant metastasis or withdrawal of informed consent, whichever comes first.

In this study, after a screening period of no more than 28 days, qualified subjects will be given ZKAB001 or placebo and test visits. Imaging examination will be performed every 12 weeks after the first dose until the local or distant recurrence of the disease, or the initiation of other systematic anti-tumor therapy or death, whichever come first.

The survival follow-up period starts from the last treatment to a maximum of 4 years, or to the death or loss of follow-up or withdrawal of informed consent or the sponsor terminates the study every 3 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 362 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Multicenter,Phase III Clinical Study of Recombinant Anti-PD-L1 Monoclonal Antibody (ZKAB001) for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy
Estimated Study Start Date : June 1, 2020
Estimated Primary Completion Date : June 1, 2022
Estimated Study Completion Date : June 1, 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: treatment group
ZKAB001 injection 10mg/kg once every 3 weeks for 1 cycle (Q3w), up to 16 cycles or 1 year of treatment.
Biological: Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)
Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)

Placebo Comparator: control group
placebo will given in the same way for once every 3 weeks for 1 cycle (Q3w), up to 16 cycles or 1 year of treatment.
Other: placebo

Primary Outcome Measures :
  1. One-year DFS rate [ Time Frame: 1 year ]
    The percentage of patients with no recurrence or metastasis within one year

Secondary Outcome Measures :
  1. Five-years OS rate [ Time Frame: 5 years ]
    Patients who survive within 5 years after the first dose.

  2. adverse events [ Time Frame: 5 years ]
    Incidence and severity of adverse events

  3. Immunogenecity of ZKAB001 [ Time Frame: 1 year ]
    To evaluated the number of subjects presenting detectable anti drug antibodies (ADAs).

  4. PD-L1 expression [ Time Frame: 1 year ]
    Correlation between PD-L1 expression level and clinical efficacy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Voluntarily participate in the trial and sign the informed consent form.
  • Age ≥ 12 years old, both male and female.
  • High-grade osteosarcoma diagnosed by histopathology (Ennecking stage II) ,radical surgery (R0 resection) and the adjuvant chemotherapy was confirmed by investigators. The end of adjuvant chemotherapy was no more than 12 weeks.
  • Chemotherapy with more than two drugs must be used; the accumulated dose of doxorubicin should not be less than 300mg/m^2 (including converted dose); the total course of chemotherapy before and after operation should not be less than 12 times, the starting time of postoperative chemotherapy should not exceed 30 days, and the time of postoperative chemotherapy should not exceed 40 weeks.
  • The score of the Eastern Cooperative Oncology Group (ECOG) is 0-1.
  • The estimated survival time is more than 3 months.
  • The functions of important organs meet the following requirements;

    1. Absolute neutrophil count ≥ 1.5 × 10^9 / L.
    2. Platelet count ≥ 75 × 10^9 /L.
    3. Hemoglobin ≥ 90g/L.
    4. Serum albumin ≥ 28g/L.
    5. Total bilirubin ≤ 1.5 × ULN;ALT, AST ≤ 2.5 × ULN.
    6. Serum creatinine ≤ 1.25 × ULN or endogenous creatinine clearance ≥ 50mL/min (using standard Crockcroft-Gault formula).
    7. Thyroid function: thyroid stimulating hormone (TSH) is normal. If TSH is abnormal, free thyroxine( FT3 and FT4 )levels should be examined. Normal FT3 and FT4 levels can be enrolled.
  • Female subjects of childbearing age should take effective contraceptive methods during the study period and within 3 months after the end of the study period, and the serum human chorionic gonadotropin pregnancy test (HCG) must be negative within 7 days before enrollment.

Exclusion Criteria:

  • Local recurrence or distant metastasis;
  • There is active autoimmune disease or history of autoimmune disease (such as, but not limited to, interstitial pneumonia, uveitis, colitis, hepatitis, arthritis, glomerulonephritis, hypophysitis, hyperthyroidism, hypothyroidism, etc.), but does not include autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormones.
  • Type I diabetes with stable doses of insulin;
  • Vitiligo or cured childhood asthma / allergies in adults without medical intervention.
  • The subjects were treated with immunosuppressants, or systemic or absorbable local corticosteroids with the purpose of immunosuppression (prednisone or equivalent for more than 10mg/ days), and continued to use them within 2 weeks before enrollment.
  • Have received any form of organ transplantation, including allogeneic stem cell transplantation;
  • Previously known to be allergic to macromolecular protein preparations or to any ZKAB001 components;
  • Previous or simultaneous suffering from other malignant tumors (except those that have been cured or cancer-free for more than 5 years, such as basal cell carcinoma of the skin, carcinoma in situ of the cervix and papillary carcinoma of the thyroid, etc.);
  • Uncontrolled cardiac clinical symptoms or diseases, such as heart failure above New York Heart Association(NYHA) 2, unstable angina pectoris, myocardial infarction within 1 year, clinical supraventricular or ventricular arrhythmias requiring intervention, echocardiography shows that the left ventricular ejection fraction at rest is less than 50%; - The completion of the treatment of radiotherapy, chemotherapy, surgery and/or molecular targeted therapy is less than 3 weeks before the first dose of study drug;
  • Active infection (need to be treated with anti-bacterial, viral and/or fungal drugs), or fever of unknown origin occurred during the screening period and occurred within one week before the first dose (judged by the investigators, except the fever caused by tumor).
  • Positive for human immunodeficiency virus (HIV); untreated active hepatitis B (hepatitis B surface antigen is positive and peripheral blood HBV-DNA titer ≥ 1000IU/ml or comply with local positive criteria) and/or hepatitis C (hepatitis C antibody is positive and HCV-RNA is higher than the lower limit)
  • Patients with active pulmonary tuberculosis infection found by medical history or CT examination, or patients with active pulmonary tuberculosis infection within one year before entering the group, or patients with active pulmonary tuberculosis infection history more than one year ago but without formal treatment;
  • Participating in other clinical studies, or less than 4 weeks from the end of the previous clinical study;
  • Other systemic anti-tumor therapy may be received during the study period;
  • Previously received other PD-1 and / or PD-L1, or CTLA-4 antibody therapy, or other drug therapy for immune receptor modulators;
  • The live vaccine was vaccinated within 4 weeks before screening.
  • Known history of psychotropic substance abuse, alcohol abuse or drug use;
  • Pregnant or lactating women;
  • Any mental state that hinders the understanding or provision of informed consent;
  • The investigators consider that the patient had other factors that might lead to the termination of the study, such as other serious diseases or serious laboratory abnormalities or accompanied by other factors that would affect the safety of the subjects, or family or social factors that would affect the collection of data and samples.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04359550

Layout table for location contacts
Contact: Yang Yao, Master 18930177737
Contact: Haiyan Hu, master 18930174575

Sponsors and Collaborators
Lee's Pharmaceutical Limited
Layout table for additonal information
Responsible Party: Lee's Pharmaceutical Limited Identifier: NCT04359550    
Other Study ID Numbers: NTL-LEES-2019-08
First Posted: April 24, 2020    Key Record Dates
Last Update Posted: April 29, 2020
Last Verified: April 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs